Strota/ Newsroom/ 2026-07-10

ORCHPHARMA (ORCHPHARMA): Acquisition / M&A

Strota Newsroom · session of 2026-07-10 · 10 Jul 19:32 · ORCHPHARMA stock page →

Orchid Pharma Limited has informed the Exchange regarding 'Update related to the Scheme of Amalgamation of Dhanuka Labor… Historically, acquisition / m&a events have moved ORCHPHARMA-type stocks in the bullish direction 48.9% of the next sessions (n=141).

Orchid Pharma has informed the National Stock Exchange of an update to the scheme of amalgamation under which Dhanuka Laboratories will merge into the company, according to an exchange filing dated 10 July. The filing, made under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements, provides no additional financial terms or timeline beyond the procedural update.

Events like this — acquisition or merger announcements — have historically produced mixed outcomes. Across 141 comparable past events, the win rate stands at 48.9% with a net edge of 0.213 percentage points, per Strota's base rate data. This means slightly under half of such announcements have been followed by favourable price movement in the studied sample; the figure describes past patterns across many stocks, not a forecast for Orchid Pharma specifically.

The stock currently trades at a price-to-earnings multiple of 246.96 and a price-to-book ratio of 3.99, with earnings per share at ₹4.1. Market capitalisation is ₹5,136 crore. The Nifty rose 1.02% on the session.

The filing confirms regulatory compliance and continued progress on the amalgamation, but does not establish valuation impact, synergy estimates, or shareholder approval timelines. The historical base rate offers context on how markets have processed similar corporate events elsewhere, not guidance on this transaction's outcome.

The catalyst

Orchid Pharma Limited has informed the Exchange regarding 'Update related to the Scheme of Amalgamation of Dhanuka Laboratories Limited ("Amalgamating Company") with Orchid Pharma Limited ("Amalgamated Company/Company") and their respective shareholdersand creditors ("the Scheme") under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), as amended.'. (filing · NSE)

What the data shows after this event

Across Strota's backtest of past filings, Acquisition / M&A shows no reliable next-session edge — the move went bullish in about 48.9% of next sessions (net 0.213% after drift and cost, n=141). A base rate, not a forecast for this stock.

ORCHPHARMA right now

P/E 246.96. Full ORCHPHARMA analysis →

Sources

Keep digging

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.